Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine

J Acquir Immune Defic Syndr. 2010 Sep;55(1):128-31. doi: 10.1097/QAI.0b013e3181e8ed15.

Abstract

We describe hospitalization trends of invasive pneumococcal disease (IPD) among HIV-infected adolescents and adults since the introduction of highly active antiretroviral therapy (HAART) and the 7-valent pneumococcal conjugate vaccine (PCV7) in the United States, using the nation-wide inpatient sample. We estimated national trends of IPD hospitalizations during 3 periods: 1994-1995 (pre-HAART/pre-PCV7); 1998-1999 (HAART/pre-PCV7); and 2004-2005 (HAART/ early PCV7). The number of IPD hospitalizations among HIV-infected individuals declined 49.2% between 1994/1995 and 2004/2005. Compared with 1994-1995, the adjusted odds ratio for IPD hospitalizations of HIV-infected adolescents and adults in the United States during 2004-2005 was 0.64 (95% confidence interval: 0.54 to 0.77). The decrease was observed after introduction of the PCV7.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active*
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Hospitalization / trends*
  • Humans
  • Male
  • Middle Aged
  • Pneumococcal Infections / epidemiology*
  • Pneumococcal Infections / immunology
  • Pneumococcal Vaccines / immunology*
  • United States
  • Vaccination / statistics & numerical data*
  • Young Adult

Substances

  • Anti-HIV Agents
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Pneumococcal Vaccines